Sino Biological,Inc.

Equities

301047

CNE100004Q23

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 15/07/2024 BST			5-day change	1st Jan Change
61.53 ^CNY	+0.29%		+1.25%	-25.33%

07-03	Tranche Update on Sino Biological,Inc.'s Equity Buyback Plan announced on February 23, 2024.	CI
06-05	InDevR, Inc. and Sino Biological,Inc. Team Up to Deliver Multiplexed Analytical Solutions for mRNA Vaccine and Cell & Gene Therapy	CI

Tranche Update on Sino Biological,Inc.'s Equity Buyback Plan announced on February 23, 2024.

July 03, 2024 at 08:33 pm

From April 1, 2024 to June 30, 2024, the company has repurchased 883,800 shares, representing 0.69% for CNY 61.06 million. With this, the company has completed the repurchase of 2,323,409 shares, representing 1.81% for CNY 164.81 million under the buyback announced on February 23, 2024.

Latest news about Sino Biological,Inc.

Tranche Update on Sino Biological,Inc.'s Equity Buyback Plan announced on February 23, 2024.	07-03	CI
InDevR, Inc. and Sino Biological,Inc. Team Up to Deliver Multiplexed Analytical Solutions for mRNA Vaccine and Cell & Gene Therapy	06-05	CI
Sino Biological,Inc. Approves Cash Dividend for the Year 2023	05-15	CI
Sino Biological,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-28	CI
Sino Biological,Inc. completed the acquisition of SignalChem Biotech Inc. from Signalchem Lifesciences Corporation.	04-25	CI
Sino Biological,Inc. Proposes Final Cash Dividend for the Year 2023	04-23	CI
Sino Biological,Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-23	CI
Tranche Update on Sino Biological,Inc.'s Equity Buyback Plan announced on February 23, 2024.	04-02	CI
Sino Biological,Inc. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 19, 2024.	02-22	CI
Bio-Link Pharmaceutical Technology Co., Ltd. announced that it has received funding from Cathay Capital Private Equity SAS, Sino Biological,Inc., Suzhou GSL Venture Capital Management Company, Beijing GSR United Capital Management Consulting Co., Ltd., Tianjin Qianxi Investment Management Partnership Ent. (L.P.), Shanghai Pudong Haiwang Private Fund Management Co., Ltd. and other investors	02-20	CI
Sino Biological,Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23	CI
Sino Biological to Acquire Canada’s SignalChem Biotech for $48 Million	23/10/23	MT
Sino Biological,Inc. entered into Share Purchase Agreement to acquire SignalChem Biotech Inc. from Signalchem Lifesciences Corporation for CAD 65.85 million.	19/10/23	CI
Sino Biological,Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	27/08/23	CI
Certain A Shares of Sino Biological Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2023.	16/08/23	CI
Sino Biological Unit to Lease Beijing Property to Shenzhou Cell Engineering	26/05/23	MT
Sino Biological Buys Land for 918 Million Yuan	23/05/23	MT
Sino Biological,Inc Approves the Final Cash Dividend for the Year 2022, Payable on 24 May 2023	16/05/23	CI
Sino Biological,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Sino Biological,Inc. Proposes Final Cash Dividend for the Year 2022	24/04/23	CI
Sino Biological,Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/04/23	CI
Sino Biological,Inc. Approves Board Elections	23/03/23	CI
PhaBuilder announced that it has received $53.4 million in funding from Sino Biological,Inc., Beijing Zhonghai Investment Management Co., Ltd., Shanghai Free Trade Zone Equity Fund Management Co., Ltd., Chengtong Fund Management Co., Ltd., CNPC Kunlun Capital Co., Ltd., Shanghai Lingang Innovation Center Co., Ltd.	01/02/23	CI
Sino Biological to Form 1 Billion Yuan Industrial Investment Fund	20/12/22	MT
Investors bet China's rally on easing COVID curbs will be furious but fleeting	05/12/22	RE

Chart Sino Biological,Inc.

Duration

Period

More charts

Company Profile

Sino Biological Inc is a China-based biotechnology company engaged in the research and development, production, sales and technical services of biological reagents. The Company's main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services. The Company operates in the domestic market and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Sino Biological,Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

61.53 CNY

Average target price

96 CNY

Spread / Average Target

+56.02%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SINO BIOLOGICAL,INC.	-25.33%	1.06B
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+45.89%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research